Corvus Pharmaceuticals, Inc. (CRVS): who owns it and who trades it
As of Nov 16, 2026, CRVS insiders reported 7 purchases worth $384K in the last 12 months. The largest buyer was David Scott Moore (Director), with $250K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Corvus Pharmaceuticals
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CRVS
173 funds and institutions reported CRVS shares worth $1.1B at the end of Q2 2026, about 84% of the company. The largest holder is Orbimed Advisors LLC with 8.5%.
Funds and institutions (13F) 84%Everyone else 16%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Orbimed Advisors LLC | 7.17M | 8.53% | $107M | No change |
| BlackRock, Inc. | 7.14M | 8.50% | $107M | +16% |
| State Street Corp | 4.47M | 5.33% | $66.8M | +25% |
| T. Rowe Price Associates | 3.79M | 4.51% | $56.6M | +30% |
| Vanguard Capital Management LLC | 3.29M | 3.92% | $49.2M | +2% |
| Adams Street Partners LLC | 3.28M | 3.90% | $48.9M | No change |
| Vivo Capital, LLC | 2.81M | 3.34% | $41.9M | No change |
| Wellington Management Group LLP | 2.73M | 3.25% | $40.8M | +18% |
| Perceptive Advisors LLC | 2.67M | 3.18% | $39.9M | +16% |
| Deep Track Capital, LP | 2.49M | 2.97% | $37.2M | No change |
| Braidwell LP | 2.13M | 2.53% | $31.8M | +21% |
| Geode Capital Management, LLC | 1.85M | 2.21% | $27.7M | +8% |
| Foresite Capital Management VI LLC | 1.83M | 2.18% | $27.4M | No change |
| Goldman Sachs Group Inc | 1.58M | 1.88% | $23.6M | +2% |
| Hood River Capital Management LLC | 1.57M | 1.87% | $23.5M | +18% |
| Morgan Stanley | 1.34M | 1.60% | $20.1M | -46% |
| Boxer Capital Management, LLC | 1.10M | 1.31% | $16.4M | No change |
| Catalio Capital Management, LP | 1.08M | 1.29% | $16.1M | +21% |
| Millennium Management LLC | 1.05M | 1.25% | $15.7M | +21% |
| Vanguard Portfolio Management LLC | 814,750 | 0.97% | $12.2M | +22% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CRVS insiders reported $384K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Jeffrey Arcara | Chief Business Officer | Purchase | 503 | $10.37 | $5.2K | Form 4 |
| Nov 13, 2026 | Jeffrey Arcara | Chief Business Officer | Purchase | 500 | $10.71 | $5.4K | Form 4 |
| Nov 12, 2026 | Jeffrey Arcara | Chief Business Officer | Purchase | 497 | $11.12 | $5.5K | Form 4 |
| Nov 11, 2026 | Jeffrey Arcara | Chief Business Officer | Purchase | 3,000 | $11.46 | $34.4K | Form 4 |
| Jun 11, 2026 | David Scott Moore | Director | Purchase | 21,700 | $11.53 | $250K | Form 4 |
| May 18, 2026 | Richard A Md Miller | CEO | Purchase | 5,000 | $12.05 | $60.2K | Form 4 |
| May 18, 2026 | Richard A Md Miller | CEO | Purchase | 1,932 | $12.01 | $23.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David Scott Moore | Director | $250K | – | Jun 11, 2026 |
| Richard A Md Miller | President and CEO, Director | $83.5K | – | May 18, 2026 |
| Jeffrey Arcara | Chief Business Officer | $50.5K | – | Nov 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CRVS short interest
Very high short interest. 21.1% of CRVS shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went down 6%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17.76M CRVS shares were sold short, 21.1% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 942,325 shares, buying them all back would take about 18.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17.76M | 21.11% | -1% | 942,325 | 18.9 |
| Oct 15, 2026 | 17.97M | 21.36% | +1% | 1.20M | 14.9 |
| Sep 30, 2026 | 17.80M | 21.16% | +4% | 1.34M | 13.3 |
| Sep 15, 2026 | 17.18M | 20.42% | -10% | 946,307 | 18.2 |
| Aug 31, 2026 | 19.02M | 22.61% | -1% | 641,670 | 29.6 |
| Aug 14, 2026 | 19.13M | 22.74% | +4% | 849,105 | 22.5 |
| Jul 31, 2026 | 18.31M | 21.80% | +1% | 813,944 | 22.5 |
| Jul 15, 2026 | 18.06M | 21.50% | -4% | 1.43M | 12.6 |
| Jun 30, 2026 | 18.82M | 22.41% | +5% | 1.52M | 12.4 |
| Jun 15, 2026 | 17.88M | 21.29% | +3% | 1.24M | 14.4 |
| May 29, 2026 | 17.32M | 20.63% | -8% | 2.05M | 8.4 |
| May 15, 2026 | 18.91M | 22.51% | +3% | 1.58M | 12.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Corvus Pharmaceuticals company events
Corvus Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 22, 2026LeadershipIan T. Clark delivered notice of his intention to resign from the board of directors of Corvus Pharmaceuticals, Inc., effective as of July 22, 2026. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 14, 2026AnnouncementThe trial enrolled 72 patients with moderate-to-severe atopic dermatitis that previously failed one prior topical or systemic therapy. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 23, 2026LeadershipThe Board of Directors of Corvus Pharmaceuticals, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Andrew C. Chan, M.D., Ph.D., to the Board, effective April 23, 2026. Filing
- Mar 13, 2026AgreementThe Company entered into an Amended and Restated Open Market Sale Agreement SM, with Jefferies LLC, to sell shares of the Company’s common stock, par value $0.0001 per share, from time to time through Jefferies acting as sales agent, having a maximum aggregate offering price of up to $200 million. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Jan 23, 2026AnnouncementCorvus Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein, relating to the sale and issuance in an underwritten public offering by the Company of 7,900,677 shares of its common… Filing
- Jan 20, 2026AnnouncementIn connection with the proposed registered underwritten public offering, Corvus Pharmaceuticals, Inc. notified Jefferies LLC that it has suspended the offering of any shares of its common stock, par value $0.0001 per share, pursuant to the prospectus supplement filed with the Securities and… Filing
- Jan 20, 2026AnnouncementBased on the encouraging results from cohorts 1-3, cohort 4 was prospectively designed to support and potentially extend the clinical results obtained in the initial cohorts. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Corvus Pharmaceuticals financials
Famous investors that hold CRVS
5 of the 50 well-known investors we track reported holding CRVS in their latest 13F filing. The largest position is Ken Fisher's, worth $12M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 1.04M | $12M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 605,644 | $7M | 0.0% | -42% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 435,146 | $5M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 399,918 | $4.6M | 0.0% | +0% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 48,984 | $564K | 0.0% | +123% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CRVS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.0% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.0% |
Questions about Corvus Pharmaceuticals, Inc. (CRVS) stock
Who owns the most CRVS stock?
The largest reported owner of Corvus Pharmaceuticals, Inc. (CRVS) is Orbimed Advisors LLC, with 8.5% of the company. In total, 173 funds and institutions reported holding CRVS at the end of Q2 2026, together about 84% of the shares. See the largest owners.
Are CRVS insiders buying or selling?
In the last 12 months, CRVS insiders reported 7 open-market purchases worth $384K and no sales. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in CRVS?
As of Oct 30, 2026, 17.76M CRVS shares were sold short, 21.1% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 942,325 shares, buying them all back would take about 18.9 trading days (days to cover). See the history.
Which famous investors hold CRVS?
5 of the 50 well-known investors we track reported CRVS in their latest 13F filing, including Ken Fisher, Israel Englander, Steve Cohen. The largest position is worth $12M. See all holders.
Executive pay
Corvus Pharmaceuticals's chief executive was paid a total of $7M for the year ended Dec 31, 2025, up 129% from $3.1M the year before. In the last 12 months, Corvus Pharmaceuticals's executives and directors bought $384K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.